U.S. markets closed
  • S&P Futures

    3,837.00
    +17.75 (+0.46%)
     
  • Dow Futures

    31,924.00
    +148.00 (+0.47%)
     
  • Nasdaq Futures

    12,381.50
    +84.25 (+0.69%)
     
  • Russell 2000 Futures

    2,210.60
    +9.80 (+0.45%)
     
  • Crude Oil

    65.45
    +0.40 (+0.61%)
     
  • Gold

    1,682.20
    +4.20 (+0.25%)
     
  • Silver

    25.25
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1853
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3826
    +0.0004 (+0.03%)
     
  • USD/JPY

    109.1750
    +0.2740 (+0.25%)
     
  • BTC-USD

    53,310.37
    +1,578.53 (+3.05%)
     
  • CMC Crypto 200

    1,077.07
    +52.86 (+5.16%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,685.41
    -57.84 (-0.20%)
     

Syneos Health to Host Virtual Analyst and Investor Event on December 8, 2020

  • Oops!
    Something went wrong.
    Please try again later.
Syneos Health, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), will host an Analyst and Investor Event on Tuesday, December 8, 2020, from 9:00 a.m. to approximately 11:30 a.m. EST.

The event, to be held virtually, will include presentations from Syneos Health leadership about the Company’s unique product development model and plan to drive accelerated growth in the evolving healthcare environment.

A live webcast, including audio, video, presentation materials and an archived replay, will be available on the Company’s Investor Relations website at investor.syneoshealth.com. Participants can pre-register and also access the webcast directly at SyneosHealthInvestorDay.com.

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Contacts

Investor Relations:

Press/Media:

Ronnie Speight

Danielle DeForge

Senior Vice President, Investor Relations

Vice President, External Communications

+1 919 745 2745

+1 202 210 5992

Investor.Relations@syneoshealth.com

danielle.deforge@syneoshealth.com